Cargando…

Dramatic Response of Nail Psoriasis to Infliximab

Nail psoriasis, affecting up to 50% of psoriatic patients, is an important cause of serious psychological and physical distress. Traditional treatments for nail psoriasis, which include topical or intralesional corticosteroids, topical vitamin D analogues, photochemotherapy, oral retinoids, methotre...

Descripción completa

Detalles Bibliográficos
Autores principales: Safa, Gilles, Darrieux, Laure
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099188/
https://www.ncbi.nlm.nih.gov/pubmed/21629846
http://dx.doi.org/10.1155/2011/107928
_version_ 1782204045285392384
author Safa, Gilles
Darrieux, Laure
author_facet Safa, Gilles
Darrieux, Laure
author_sort Safa, Gilles
collection PubMed
description Nail psoriasis, affecting up to 50% of psoriatic patients, is an important cause of serious psychological and physical distress. Traditional treatments for nail psoriasis, which include topical or intralesional corticosteroids, topical vitamin D analogues, photochemotherapy, oral retinoids, methotrexate, and cyclosporin, can be time-consuming, painful, or limited by significant toxicities. Biological agents may have the potential to revolutionize the management of patients with disabling nail psoriasis. We present another case of disabling nail psoriasis that responded dramatically to infliximab.
format Text
id pubmed-3099188
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30991882011-05-31 Dramatic Response of Nail Psoriasis to Infliximab Safa, Gilles Darrieux, Laure Case Rep Med Case Report Nail psoriasis, affecting up to 50% of psoriatic patients, is an important cause of serious psychological and physical distress. Traditional treatments for nail psoriasis, which include topical or intralesional corticosteroids, topical vitamin D analogues, photochemotherapy, oral retinoids, methotrexate, and cyclosporin, can be time-consuming, painful, or limited by significant toxicities. Biological agents may have the potential to revolutionize the management of patients with disabling nail psoriasis. We present another case of disabling nail psoriasis that responded dramatically to infliximab. Hindawi Publishing Corporation 2011 2011-05-10 /pmc/articles/PMC3099188/ /pubmed/21629846 http://dx.doi.org/10.1155/2011/107928 Text en Copyright © 2011 G. Safa and L. Darrieux. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Safa, Gilles
Darrieux, Laure
Dramatic Response of Nail Psoriasis to Infliximab
title Dramatic Response of Nail Psoriasis to Infliximab
title_full Dramatic Response of Nail Psoriasis to Infliximab
title_fullStr Dramatic Response of Nail Psoriasis to Infliximab
title_full_unstemmed Dramatic Response of Nail Psoriasis to Infliximab
title_short Dramatic Response of Nail Psoriasis to Infliximab
title_sort dramatic response of nail psoriasis to infliximab
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3099188/
https://www.ncbi.nlm.nih.gov/pubmed/21629846
http://dx.doi.org/10.1155/2011/107928
work_keys_str_mv AT safagilles dramaticresponseofnailpsoriasistoinfliximab
AT darrieuxlaure dramaticresponseofnailpsoriasistoinfliximab